PMID- 28371189
OWN - NLM
STAT- MEDLINE
DCOM- 20180521
LR  - 20181202
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
VI  - 33
IP  - 6
DP  - 2017 Sep
TI  - Effect of GLP-1 and GIP on C-peptide secretion after glucagon or mixed meal 
      tests: Significance in assessing B-cell function in diabetes.
LID - 10.1002/dmrr.2899 [doi]
AB  - BACKGROUND: The aim of the study was to investigate the different B-cell 
      responses after a glucagon stimulation test (GST) versus mixed meal tolerance 
      test (MMTT). METHODS: We conducted GST and MMTT in 10 healthy people (aged 
      25-40 years) and measured C-peptide, gastric inhibitory peptide (GIP) and 
      glucagon-like peptide-1 (GLP-1) at different time points after the administration 
      of 1 mg i.v. glucagon for GST or a liquid mixed meal for MMTT. RESULTS: The GST 
      stimulated C-peptide showed a mean increase of 147.1%, whereas the mean increase 
      of MMTT stimulated C-peptide was 99.82% (Deltaincrease = 47.2%). Maximum C-peptide 
      level reached with the MMTT was greater than that obtained with the GST (C-pept 
      max MMTT = 2.35 nmol/L vs C-pep max GST = 1.9 nmol/L). A positive and linear 
      correlation was found between the GST incremental area under the curve C-peptide 
      and the MMTT incremental area under the curve C-peptide (r = 0.618, P = .05). 
      After GST, there was no increment of GIP and glucagon like peptide-1 levels 
      compared to baseline levels. A positive and linear correlation between GIP and 
      C-peptide levels was observed only for the MMTT (r = 0.922, P = .008) indicating 
      that in the GST, the C-peptide response is independent of the incretin axis 
      response. CONCLUSIONS: Although the 2 stimulation tests may elicit a similar 
      response in C-peptide secretion, B-cell response to MMTT depends on a 
      functionally normal incretin axis. These results may have implications when 
      investigating the B-cell response in people with diabetes and for studies in 
      which stimulated C-peptide secretion is used as primary or secondary outcome for 
      response to therapy.
CI  - Copyright (c) 2017 John Wiley & Sons, Ltd.
FAU - Guglielmi, C
AU  - Guglielmi C
AD  - Unit of Endocrinology and Diabetes, University Campus Bio Medico of Rome, Rome, 
      Italy.
FAU - Del Toro, R
AU  - Del Toro R
AD  - Unit of Endocrinology and Diabetes, University Campus Bio Medico of Rome, Rome, 
      Italy.
FAU - Lauria, A
AU  - Lauria A
AD  - Unit of Endocrinology and Diabetes, University Campus Bio Medico of Rome, Rome, 
      Italy.
FAU - Maurizi, A R
AU  - Maurizi AR
AD  - Unit of Endocrinology and Diabetes, University Campus Bio Medico of Rome, Rome, 
      Italy.
FAU - Fallucca, S
AU  - Fallucca S
AD  - Unit of Endocrinology and Diabetes, University Campus Bio Medico of Rome, Rome, 
      Italy.
FAU - Cappelli, A
AU  - Cappelli A
AD  - Unit of Endocrinology and Diabetes, University Campus Bio Medico of Rome, Rome, 
      Italy.
FAU - Angeletti, S
AU  - Angeletti S
AD  - Clinical Pathology and Microbiology Laboratory, University Campus Bio Medico of 
      Rome, Rome, Italy.
FAU - Lachin, J M
AU  - Lachin JM
AD  - The Biostatistics Center, George Washington University, Rockville, Maryland, USA.
FAU - Pozzilli, P
AU  - Pozzilli P
AUID- ORCID: 0000-0001-5090-636X
AD  - Unit of Endocrinology and Diabetes, University Campus Bio Medico of Rome, Rome, 
      Italy.
AD  - Centre of Diabetes, Blizard Institute, Queen Mary University of London, Barts and 
      The London School of Medicine, London, UK.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20170509
PL  - England
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
RN  - 0 (C-Peptide)
RN  - 59392-49-3 (Gastric Inhibitory Polypeptide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9007-92-5 (Glucagon)
SB  - IM
MH  - Adult
MH  - C-Peptide/*metabolism
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/*diagnosis/physiopathology
MH  - *Diagnostic Techniques, Endocrine
MH  - Eating/physiology
MH  - Female
MH  - Gastric Inhibitory Polypeptide/*pharmacology
MH  - Glucagon/*administration & dosage
MH  - Glucagon-Like Peptide 1/*pharmacology
MH  - Humans
MH  - Insulin-Secreting Cells/*drug effects/physiology
MH  - Male
MH  - *Meals
MH  - Stimulation, Chemical
OTO - NOTNLM
OT  - B-cell function
OT  - C-peptide
OT  - diabetes
OT  - glucagon stimulation test
OT  - incretin axis
OT  - mixed meal tolerance test
EDAT- 2017/04/04 06:00
MHDA- 2018/05/22 06:00
CRDT- 2017/04/04 06:00
PHST- 2016/12/20 00:00 [received]
PHST- 2017/03/16 00:00 [revised]
PHST- 2017/03/18 00:00 [accepted]
PHST- 2017/04/04 06:00 [pubmed]
PHST- 2018/05/22 06:00 [medline]
PHST- 2017/04/04 06:00 [entrez]
AID - 10.1002/dmrr.2899 [doi]
PST - ppublish
SO  - Diabetes Metab Res Rev. 2017 Sep;33(6). doi: 10.1002/dmrr.2899. Epub 2017 May 9.